F8 and hemophilia A: Hemlibra® (Emicizumab) is the only bispecific antibody approved for the treatment of Hemophilia A, which works by restoring the function of the missing factor VIII (FVIII) by bridging FIXa and FX and therefore enabling hemostasis.58